Paul Glavine bought $1.0M of HELP
Chief Growth Officer at Helus Pharma Inc.. 90,000 shares at an average of $11.59, traded Aug 31, 2026, filed Sep 9, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.0M at market
- 0Relative to holdingsHoldings up 2.3%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000912282-26-001246, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | POpen-market purchase Common Shares | +90,000 | $11.59 | $1.0M | 4,071,252 | 34 d ago |
Related signals
Other insiders at Helus Pharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | Helus Pharma Inc. | Greg Cavers Chief Financial Officer | $39k 3,000 shares | - | |
| 75Notable | Helus Pharma Inc. | Michael Halstead Chief Executive Officer | $1.3M 100,000 shares | +146% | |
| 65Notable | Helus Pharma Inc. | Eric H. L. So Executive Chair | $1.2M 100,000 shares | +2% | |
| 60Notable | Helus Pharma Inc. | Paul Glavine Chief Growth Officer | $1.2M 100,000 shares | +2% | |
| 60Notable | Helus Pharma Inc. | Paul Glavine Chief Growth Officer | $1.2M 100,000 shares | +2% | |
| 53Moderate | Helus Pharma Inc. | Paul Glavine Chief Growth Officer | $1.2M 100,000 shares | +2% | |
| 58Moderate | Helus Pharma Inc. | Eric H. L. So Executive Chair | $1.2M 100,000 shares | +2% | |
| 53Moderate | Helus Pharma Inc. | Eric H. L. So Executive Chair | $1.1M 95,000 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.